Abstract
Previous studies have shown that the viral Jun (v-Jun) oncoprotein induces marked alterations in cell cycle control, which are associated with, and may be caused by, increased cdk2 kinase activity. Since p21 CIP1 is an important regulator of cdk2, we investigated whether aberrant expression of this cyclin-dependent kinase inhibitor might contribute to cell cycle deregulation by v-Jun. We find that the basal levels of p21 CIP1 mRNA and protein expression are greatly reduced in chick embryo fibroblasts (CEF) transformed by v-Jun, and that v-Jun blocks the increases in p21 CIP1 expression that normally accompany growth inhibition induced by serum deprivation or confluency in untransformed CEF. Importantly, ectopic expression of p21 CIP1 in v-Jun-transformed CEF inhibits both cdk2 kinase activity and cell cycle progression, indicating that these alterations in p21 CIP1 expression are likely to be functionally significant for growth deregulation. We also investigated the mechanism through which v-Jun disturbs p21 CIP1 expression and the possible involvement of a known p21 CIP1 regulator, p53, as an intermediate in this process. This analysis revealed that repression is mediated primarily at the level of p21 CIP1 gene transcription, however the mechanism is complex; both p53-dependent and -independent mechanisms contribute as judged by analysis of p21 CIP1 promoter mutants and other assays of p53 transcriptional activity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bader AG, Schneider ML, Bister K and Hartl M . (2001). Oncogene, 20, 7524–7535.
Blalock WL, Pearce M, Steelman LS, Franklin RA, McCarthy SA, Cherwinski H, McMahon M and McCubrey JA . (2000). Oncogene, 19, 526–536.
Chen BK and Chang WC . (2000). Proc. Natl. Acad. Sci. USA, 97, 10406–10411.
Claassen GF and Hann SR . (2000). Proc. Natl. Acad. Sci. USA, 97, 9498–9503.
Clark W, Black EJ, MacLaren A, Kruse U, LaThangue N, Vogt PK and Gillespie DA . (2000). Mol. Cell. Biol., 20, 2529–2542.
Clark W and Gillespie DA . (1997). Cell Growth Differ., 8, 371–380.
Coller HA, Grandori C, Tamayo P, Colbert T, Lander ES, Eisenman RN and Golub TR . (2000). Proc. Natl. Acad. Sci. USA, 97, 3260–3265.
Cox LS . (1997). J. Pathol., 183, 134–140.
Datto MB, Yu Y and Wang XF . (1995). J. Biol. Chem., 270, 28623–28628.
el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B . (1993). Cell, 75, 817–825.
Erhardt JA and Pittman RN . (1998). Oncogene, 16, 443–451.
Fu S, Bottoli I, Goller M and Vogt PK . (1999). Proc. Natl. Acad. Sci. USA, 96, 5716–5721.
Fu SL, Waha A and Vogt PK . (2000). Oncogene, 19, 3537–3545.
Gao M, Morgan I and Vogt PK . (1996). Cancer Res., 56, 4229–4235.
Gartel AL and Tyner AL . (1999). Exp. Cell Res., 246, 280–289.
Gartel AL, Ye X, Goufman E, Shianov P, Hay N, Najmabadi F and Tyner AL . (2001). Proc. Natl. Acad. Sci. USA, 98, 4510–4515.
Gervais JL, Seth P and Zhang H . (1998). J. Biol. Chem., 273, 19207–19212.
Givol I, Givol D, Rulong S, Resau J, Tsarfaty I and Hughes SH . (1995). Oncogene, 11, 2609–2618.
Haapajarvi T, Kivinen L, Heiskanen A, des Bordes C, Datto MB, Wang XF and Laiho M . (1999). Exp. Cell Res., 248, 272–279.
Hadman M, Gabos L, Loo M, Sehgal A and Bos TJ . (1996). Oncogene, 12, 135–142.
Hall M and Peters G . (1996). Adv. Cancer Res., 68, 67–108.
Hartl M and Bister K . (1995). Proc. Natl. Acad. Sci. USA, 92, 11731–11735.
Hartwell LH and Kastan MB . (1994). Science, 266, 1821–1828.
Juven T, Barak Y, Zauberman A, George DL and Oren M . (1993). Oncogene, 8, 3411–3416.
Kardassis D, Papakosta P, Pardali K and Moustakas A . (1999). J. Biol. Chem., 274, 29572–29581.
Kilbey A, Black EJ, Unlu M and Gillespie DA . (1996). Oncogene, 12, 2409–2418.
LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A and Harlow E . (1997). Genes Dev., 11, 847–862.
MacLaren A, Clark W and Gillespie DA . (2000). Oncogene, 19, 5906–5918.
Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, Vogelstein B and Jacks T . (1995). Genes Dev., 9, 935–944.
Maki Y, Bos TJ, Davis C, Starbuck M and Vogt PK . (1987). Proc. Natl. Acad. Sci. USA, 84, 2848–2852.
Mitchell KO and El-Deiry WS . (1999). Cell Growth Differ., 10, 223–230.
Ries S, Biederer C, Woods D, Shifman O, Shirasawa S, Sasazuki T, McMahon M, Oren M and McCormick F . (2000). Cell, 103, 321–330.
Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D and Goldberg AL . (1994). Cell, 78, 761–771.
Schreiber M, Kolbus A, Piu F, Szabowski A, U Mh-S, Tian J, Karin M, Angel P and Wagner EF . (1999). Genes Dev., 13, 607–619.
Shaulian E, Schreiber M, Piu F, Beeche M, Wagner EF and Karin M . (2000). Cell, 103, 897–907.
Tsao YP, Li LY, Tsai TC and Chen SL . (1996). J. Virol., 70, 7535–7539.
Vogt PK . (2001). Oncogene, 20, 2365–2377.
Vogt PK and Bos TJ . (1990). Adv. Cancer Res., 55, 1–35.
Waldman T, Lengauer C, Kinzler KW and Vogelstein B . (1996). Nature, 381, 713–716.
Wang CH, Tsao YP, Chen HJ, Chen HL, Wang HW and Chen SL . (2000). Biochem. Biophys. Res. Commun., 270, 303–310.
Wu RC and Schonthal AH . (1997). J. Biol. Chem., 272, 29091–29098.
Acknowledgements
This work is supported by Cancer Research UK. The authors thank the following for the provision of reagents—M Oren, X Wang, N Perkins, and K Ryan and J Wyke for comments on the manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Maclaren, A., Clark, W., Black, E. et al. v-Jun stimulates both cdk2 kinase activity and G1/S progression via transcriptional repression of p21 CIP1. Oncogene 22, 2383–2395 (2003). https://doi.org/10.1038/sj.onc.1206329
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206329